Phaseline

Companies › Bazelet Nehushtan

Bazelet Nehushtan: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Psychiatry; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Terpenes-Enriched CBD-Predominant Oil (T1/C28)
Cannabinoid system modulation with CBD and minor THC with terpenes
CNR1, CNR2Phase 2AutismDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07199218Terpenes-Enriched CBD-Predominant Oil (T1/C28)Phase 2AutismPsychiatryDec 2027
NCT07199218Terpenes-Enriched CBD-Predominant Oil (T1/C28)Phase 2AutismPsychiatryDec 2027

Targets

CNR1 (1) CNR2 (1)

Companies with the same targets

IGC Pharma Zynerba Pharmaceuticals Incannex Healthcare Vertanical Alasht Pharmed Jazz Pharmaceuticals Sinfatin Skye Bioscience PleoPharma Laboratorio Elea Phoenix

Companies built like this

PleoPharma NeuroRx Autobahn Therapeutics atai Therapeutics Arialys Australia

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.